The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is a huge mover today! About 5.78M shares traded hands. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has risen 46.72% since April 6, 2016 and is uptrending. It has outperformed by 44.76% the S&P500.
The move comes after 5 months negative chart setup for the $1.90 billion company. It was reported on Nov, 8 by Barchart.com. We have $8.29 PT which if reached, will make NASDAQ:ARIA worth $171.00 million less.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) Ratings Coverage
Out of 7 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 3 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 43% are positive. Ariad Pharmaceuticals has been the topic of 12 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was initiated by Suntrust Robinson on Wednesday, October 5 with “Buy”. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm has “Underweight” rating given on Monday, October 24 by JP Morgan. Leerink Swann initiated the stock with “Outperform” rating in Monday, September 26 report. The stock of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has “Underweight” rating given on Tuesday, January 19 by Barclays Capital. As per Friday, July 29, the company rating was maintained by Barclays Capital. The stock has “Mkt Perform” rating given by JMP Securities on Tuesday, October 25. Barclays Capital maintained Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Wednesday, May 11 with “Underweight” rating. The rating was initiated by SunTrust on Wednesday, October 5 with “Buy”. The rating was initiated by Deutsche Bank on Thursday, November 3 with “Hold”.
According to Zacks Investment Research, “Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology. The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.4 in 2016 Q2. Its up 0.73, from 0.67 in 2016Q1. The ratio increased, as 19 funds sold all Ariad Pharmaceuticals, Inc. shares owned while 44 reduced positions. 30 funds bought stakes while 58 increased positions. They now own 131.89 million shares or 0.58% less from 132.66 million shares in 2016Q1.
Grp Incorporated has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Deutsche Bank Ag last reported 0.01% of its portfolio in the stock. Alphamark Advisors Lc last reported 172 shares in the company. California Employees Retirement, a California-based fund reported 352,900 shares. Tiaa Cref Trust Com Fsb Mo has 30,000 shares for 0% of their US portfolio. The New York-based Citigroup has invested 0% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Granite Point Capital Mgmt L P has 430,890 shares for 1.37% of their US portfolio. Great West Life Assurance Can has 0% invested in the company for 21,040 shares. Commonwealth Equity Svcs has invested 0% of its portfolio in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). The Connecticut-based Point72 Asset Management Lp has invested 0.02% in Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA). Barclays Public Limited Co owns 5,805 shares or 0% of their US portfolio. Envestnet Asset Mngmt Incorporated accumulated 0% or 1,030 shares. Blackrock Fund Advsrs owns 7.83 million shares or 0.01% of their US portfolio. Tru Of Vermont holds 0% or 650 shares in its portfolio. Legal And General Grp Public Ltd Co has 0% invested in the company for 48,134 shares.
Insider Transactions: Since May 12, 2016, the stock had 0 insider buys, and 11 selling transactions for $4.01 million net activity. On Thursday, May 12 the insider Panayiotopoulos Paris bought $199,996. 76,250 shares were sold by LAVIDAS ATHANESE, worth $626,039. 25,000 shares were sold by CLACKSON TIMOTHY P, worth $262,500 on Friday, August 12. 108,569 Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares with value of $896,135 were sold by Radaelli Massimo.
More important recent Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) news were published by: Fool.com which released: “3 Things You Really Need to Know About Ariad Pharmaceuticals, Inc. Q3 Results” on November 07, 2016, also Etfdailynews.com published article titled: “Bernie Sanders Tweet Causes Ariad Pharma Stock to Plunge 14%”, Businesswire.com published: “ARIAD to Webcast Conference Call on Third Quarter 2016 Financial Results” on October 26, 2016. More interesting news about Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) was released by: Businesswire.com and their article: “ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for …” with publication date: October 31, 2016.
ARIA Company Profile
ARIAD Pharmaceuticals, Inc. (ARIAD), incorporated on April 12, 1991, is an oncology company. The Firm is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.